RECURSION PHARMACEUTICALS, INC. Finance Lease, Liability
RECURSION PHARMACEUTICALS, INC. (RXRX) had Finance Lease, Liability of $13.90 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:FinanceLeaseLiability · last filed 2026-08-05
- 2026-06-30: Finance Lease, Liability $13.90M.
- 2026-03-31: Finance Lease, Liability $16.20M.
- 2025-12-31: Finance Lease, Liability $18.34M.
- 2025-09-30: Finance Lease, Liability $20.50M.
| Period end | Finance Lease, Liability |
|---|---|
| 2026-06-30 | $13.90M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $16.20M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $18.34M 10-K · filed 2026-02-25 |
| 2025-09-30 | $20.50M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $22.60M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $24.60M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $26.65M 10-K · filed 2025-02-28 |
| 2024-09-30 | $27.64M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $29.92M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |